| Literature DB >> 36119653 |
Md Atiar Rahman1, Fauzia Mahanaz Shorobi2, Md Nazim Uddin3, Srabonti Saha1, Md Amjad Hossain4.
Abstract
Medicinally active compounds in the flavonoid class of phytochemicals are being studied for antiviral action against various DNA and RNA viruses. Quercetin is a flavonoid present in a wide range of foods, including fruits and vegetables. It is said to be efficient against a wide range of viruses. This research investigated the usefulness of Quercetin against Hepatitis C virus, Dengue type 2 virus, Ebola virus, and Influenza A using computational models. A molecular docking study using the online tool PockDrug was accomplished to identify the best binding sites between Quercetin and PubChem-based receptors. Network-pharmacological assay to opt to verify function-specific gene-compound interactions using STITCH, STRING, GSEA, Cytoscape plugin cytoHubba. Quercetin explored tremendous binding affinity against NS5A protein for HCV with a docking score of - 6.268 kcal/mol, NS5 for DENV-2 with a docking score of - 5.393 kcal/mol, VP35 protein for EBOV with a docking score of - 4.524 kcal/mol, and NP protein for IAV with a docking score of - 6.954 kcal/mol. In the network-pharmacology study, out of 39 hub genes, 38 genes have been found to interact with Quercetin and the top interconnected nodes in the protein-protein network were (based on the degree of interaction with other nodes) AKT1, EGFR, SRC, MMP9, MMP2, KDR, IGF1R, PTK2, ABCG2, and MET. Negative binding energies were noticed in Quercetin-receptor interaction. Results demonstrate that Quercetin could be a potential antiviral agent against these viral diseases with further study in in-vivo models. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-022-00132-2.Entities:
Keywords: Antiviral action; Dengue; Flavonoid; Hepatitis C virus; Influenza; Quercetin; SARSCOV-2
Year: 2022 PMID: 36119653 PMCID: PMC9477994 DOI: 10.1007/s40203-022-00132-2
Source DB: PubMed Journal: In Silico Pharmacol ISSN: 2193-9616
Fig. 1.2D structure of quercetin (Ashwini et al. 2017)
Binding affinity and ligand efficiencies estimation of quercetin with different viruses including HCV, DENV-2, EBOV, and IAV via using MM-GBSA
| Name of proteins with PDB ID | MM-GBSA (kcal/mol) | Ligand efficiency |
|---|---|---|
| NS5A (PDB ID: 4CL1) for HCV | – 50.31 | – 0.285 |
| NS5 (PDB ID: 3EVG) for DENV-2 | – 33.36 | – 0.245 |
| VP35 (PDB ID: 4IBK) for EBOV | – 35.31 | – 0.206 |
| NP specific inhibitor (PDB ID: 6J1U) for IAV | – 41.69 | – 0.316 |
Impacts of Quercetin against different viruses including HCV, DENV-2, EBOV, and IAV via molecular docking analysis
| Name of proteins with PDB ID | Docking score | Glide emodel | Glide energy | Bond interaction types | Involved amino acid residues | Distances |
|---|---|---|---|---|---|---|
| NS5A (PDB ID: 4CL1) for HCV | – 6.268 kcal/mol | – 60.248 kcal/mol | –44.298 kcal/mol | Hydrogen bond | PRO 154 | 2.78 Å |
| SER 157 | 2.46 Å | |||||
| GLN 158 | 2.76 Å | |||||
| CYS 111 | 1.99 Å | |||||
| PRO 160 | 2.54 Å | |||||
| Pi-pi stacked | TYR 153 | 5.55 Å | ||||
| Pi-alkyl | VAL 101 | 4.20 Å | ||||
| CYS 111 | 5.14 Å | |||||
| CYS 111 | 4.72 Å | |||||
| LYS 110 | 5.05 Å | |||||
| NS5 (PDB ID: 3EVG) for DENV-2 | – 5.393 kcal/mol | – 62.617 kcal/mol | – 47.496 kcal/mol | Water H-bond | HOH 546 | 2.63 Å |
| Conventional H-bond | LYS 110 | 2.19 Å | ||||
| SO 4904 | 1.62 Å | |||||
| Pi anion bond | SO 490 | 1.89 Å | ||||
| ASP 146 | 3.83 Å | |||||
| ASP 146 | 3.24 Å | |||||
| VP35 (PDB ID: 4IBK) for EBOV | 4.524 kcal/mol | – 40.324 | – 31.814 | Conventional H-bond | ALA 221 | 2.45 Å |
| ARG 225 | 2.82 Å | |||||
| DMS 403 | 3.06 Å | |||||
| VAL 294 | 3.60 Å | |||||
| Pi-alkyl bond | ILE 295 | 4.60 Å | ||||
| Pi- cation bond | LYS 248 | 4.64 Å | ||||
| LYS 248 | 4.97 Å | |||||
| NP specific inhibitor (PDB ID: 6J1U) for IAV | – 6.954 kcal/mol | – 56.237 | – 42.26 | H-bond | ASP 51 | 1.64 Å |
| SER 283 | 1.68 Å | |||||
| SER 283 | 2.61 Å | |||||
| CYS 279 | 2.68 Å | |||||
| THR 45 | 1.83 Å | |||||
| Pi alkyl bond | ALA 286 | 4.41 Å | ||||
| ALA 286 | 4.16 Å | |||||
| CYS 44 | 4.86 Å | |||||
| Amide pi stacked bond | GLY 282 | 4.22 Å |
Fig. 2Illustration of Quercetin binding mode 3D (left) and 2D (right) against different viruses including HCV (A), DENV-2 (B), EBOV (C), and IAV (D) via molecular docking analysis
Fig. 3Identifying common 39 genes that are interacted with quercetin. Interaction of common 39 genes with quercetin
Fig. 4Interaction of common 39 genes with quercetin. The Cytoscape tool was utilized to illustrate the interactions
Fig. 5The protein–protein interaction (PPI) network of common 39 genes that are interacted with quercetin in STITCH and the Swiss Target Prediction tool
Top ten hub nodes in the PPI
| Rank | Symbol | Name | Degree of interaction |
|---|---|---|---|
| 1 | AKT1 | AKT serine/threonine kinase 1 | 27 |
| 2 | EGFR | epidermal growth factor receptor | 23 |
| 3 | SRC | "SRC proto-oncogene, non-receptor tyrosine kinase | 22 |
| 4 | MMP9 | matrix metallopeptidase 9 | 16 |
| 5 | MMP2 | matrix metallopeptidase 2 | 14 |
| 5 | KDR | kinase insert domain receptor | 14 |
| 7 | IGF1R | Insulin-like growth factor 1 receptor | 12 |
| 7 | PTK2 | protein tyrosine kinase 2 | 12 |
| 9 | ABCG2 | ATP binding cassette subfamily G member 2 | 10 |
| 10 | MET | "MET proto-oncogene, receptor tyrosine kinase | 9 |
Fig. 6The top ten biological processes (BP), cellular components (CC), and molecular functions (MF) are significantly associated with quercetin-targeted genes
The significantly enriched KEGG pathways associated with genes that are interacted with quercetin
| KEGG pathways | Genes in overlap | p-value | FDR |
|---|---|---|---|
| Pathways in cancer | 11 | 1.08E-14 | 2.01E-12 |
| Focal adhesion | 9 | 2.71E-13 | 2.52E-11 |
| ErbB signaling pathway | 6 | 2.61E-10 | 1.40E-08 |
| Prostate cancer | 6 | 3.00E-10 | 1.40E-08 |
| Melanoma | 5 | 8.07E-09 | 3.00E-07 |
| VEGF signaling pathway | 5 | 1.14E-08 | 3.54E-07 |
| Progesterone-mediated oocyte maturation | 5 | 2.01E-08 | 5.35E-07 |
| Endometrial cancer | 4 | 1.96E-07 | 4.55E-06 |
| Acute myeloid leukemia | 4 | 2.85E-07 | 5.68E-06 |
| Arachidonic acid metabolism | 4 | 3.06E-07 | 5.68E-06 |
| Glioma | 4 | 4.85E-07 | 8.20E-06 |
| Adherens junction | 4 | 7.76E-07 | 1.20E-05 |
| Endocytosis | 5 | 8.78E-07 | 1.26E-05 |
| Small cell lung cancer | 4 | 1.36E-06 | 1.81E-05 |
| Leukocyte transendothelial migration | 4 | 4.95E-06 | 6.14E-05 |
| Bladder cancer | 3 | 9.36E-06 | 1.05E-04 |
| Insulin signaling pathway | 4 | 9.57E-06 | 1.05E-04 |
| ABC transporters | 3 | 1.08E-05 | 1.11E-04 |
| Non-small cell lung cancer | 3 | 2.01E-05 | 1.96E-04 |
| Steroid hormone biosynthesis | 3 | 2.12E-05 | 1.97E-04 |
| Colorectal cancer | 3 | 3.04E-05 | 2.70E-04 |
| Chemokine signaling pathway | 4 | 3.39E-05 | 2.86E-04 |
| Epithelial cell signaling in Helicobacter pylori infection | 3 | 4.02E-05 | 3.25E-04 |
| Pancreatic cancer | 3 | 4.38E-05 | 3.26E-04 |
| Renal cell carcinoma | 3 | 4.38E-05 | 3.26E-04 |
| B cell receptor signaling pathway | 3 | 5.39E-05 | 3.85E-04 |
| Gap junction | 3 | 9.28E-05 | 6.39E-04 |
| Cytokine-cytokine receptor interaction | 4 | 1.25E-04 | 8.32E-04 |
| GnRH signaling pathway | 3 | 1.31E-04 | 8.38E-04 |
| T cell receptor signaling pathway | 3 | 1.59E-04 | 9.88E-04 |
| Oocyte meiosis | 3 | 1.82E-04 | 1.09E-03 |
| Cell cycle | 3 | 2.45E-04 | 1.41E-03 |
| Neurotrophin signaling pathway | 3 | 2.51E-04 | 1.41E-03 |
| Axon guidance | 3 | 2.69E-04 | 1.47E-03 |
| Jak-STAT signaling pathway | 3 | 4.60E-04 | 2.45E-03 |
| Tryptophan metabolism | 2 | 6.95E-04 | 3.59E-03 |
| Tyrosine metabolism | 2 | 7.66E-04 | 3.85E-03 |
| Regulation of actin cytoskeleton | 3 | 1.16E-03 | 5.59E-03 |
| mTOR signaling pathway | 2 | 1.17E-03 | 5.59E-03 |
| p53 signaling pathway | 2 | 2.00E-03 | 9.28E-03 |
| Metabolism of xenobiotics by cytochrome P450 | 2 | 2.11E-03 | 9.59E-03 |
| Chronic myeloid leukemia | 2 | 2.29E-03 | 1.02E-02 |
| Fc epsilon RI signaling pathway | 2 | 2.68E-03 | 1.16E-02 |
| Apoptosis | 2 | 3.24E-03 | 1.34E-02 |
| Hematopoietic cell lineage | 2 | 3.24E-03 | 1.34E-02 |
| Fc gamma R-mediated phagocytosis | 2 | 3.93E-03 | 1.59E-02 |
| Melanogenesis | 2 | 4.34E-03 | 1.71E-02 |
| Toll-like receptor signaling pathway | 2 | 4.42E-03 | 1.71E-02 |
| Tight junction | 2 | 7.28E-03 | 2.76E-02 |
| Calcium signaling pathway | 2 | 1.29E-02 | 4.80E-02 |